IMCR - Cancer Focused Immunocore Leads The Way In TCR Therapeutics Positioned For Success: Analyst Says | Benzinga
Needham has initiated coverage on Immunocore Holdings Plc (NASDAQ: IMCR) with a Buy rating and a price target of $75.
Needham analyst Gil Blum says Immunocore has achieved a significant milestone as the pioneer in introducing a commercial-stage TCR therapeutic.
The company's inaugural product, Kimmtrak, a groundbreaking TCR-TCE in the treatment of metastatic uveal melanoma (mUM), has made a remarkable entrance into the market.
Needham notes Immunocore's primary source of value lies in its IMC-F106C program, designed to target PRAME.
This program is poised to tap into an estimated ...